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Summary.-The results of intravenous chemotherapy for advanced squamous cell
carcinoma of the head and neck in 50 patients are presented. Forty patients were
treated with methotrexate alone-3 patients showed partial regression of disease
and a further 7 were controlled for periods of up to 4 months. Of those patients
who failed to respond, or who relapsed on methotrexate, 16 were treated with com-
bination chemotherapy. One patient showed complete regression of disease, 2
partial regression and in 2 others control was achieved for up to 4 months. A
further 10 patients were treated with combination chemotherapy only, with no
previous methotrexate. In this group no objective regressions were noted and
only one patient was controlled for a period of 14 months. It is suggested that
intravenous chemotherapy in advanced squamous cell carcinoma of the head and
neck is of doubtful value.
PATIENTS AND METHODS
IN 1968 Leone, Albala and Rege reported
on 35 patients with advanced squamous cell
carcinoma of the head and neck treated by
intravenous chemotherapy using metho-
trexate as a single agent. They obtained
a 5700 remission rate and in view of their
encouraging results we adopted intravenous
methotrexate as the treatment of choice
following the failure of radiotherapy and/or
surgery to control this condition. Only
patients with squamous cell lesions are
included in this series.
Leone's regimen recommended an initial
dose of methotrexate of 60 mg/mn2 given
once weekly. Such a high initial dose had
been seen to cause severe toxicity when used
previously in other conditions. It was
therefore decided to modify the regimen,
starting with an initial dose of 15 mg and
increasing by weekly increments of 5 mg
until toxicity intervened or until a dose of
50 mg was reached. Treatment was then
continued by weekly injections at the
maximum tolerated dose. A few patients
were able to tolerate regular doses in excess
of 50 mg weekly.
In all patients the blood urea concen-
tration was measured before starting treat-
ment and a full blood count was performed
before each injection. They were examined
regularly for oral ulceration and questioned
as to whether nausea or diarrhoea had been
experienced.
Forty patients were treated on this
regimen. All had received irradiation pre-
viously and 18 had undergone some form
of major surgery for recurrent disease.
There is close co-operation at this hospital
between radiotherapists, general surgeons and
plastic surgeons and many of these patients
had been subjected to major excision and
reconstruction procedures in an attempt
to eradicate disease. Chemotherapy was
started only when radiotherapy and surgery
had failed to control the condition.
In 1970 a modification of the Costanzi
and Coltman (1969) regimen of combination
chemotherapy was employedforsolidtumours
(Hanham, Newton and Westbury, 1971).
Those patients with squamous cell carcinoma
of the head and neck who had failed to
respond to intravenous methotrexate were
transferred to this regimen. Sixteen pa-
tients were treated in this way and limitedADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
early success with combination chemo-
therapy led to its use as the initial chemo-
therapeutic regimen in a further 10 patients.
All patients were given combination
chemotherapy as a 5-day course with 3 weeks'
lapse between courses. The drugs and their
dosages are given in Table I.
TABLE I.-Combination Chemotherapy
Regimen
Day 1 Cyclophosphamide
Methotrexate
5-fluorouracil
Day 2 Vincristine
5-fluorouracil
Day 3 5-fluorouracil
Day 4 Methotrexate
5-fluorouracil
Day 5 Cyclophosphamide
Vincristine
5-fluorouracil
300 mg
25 mg
500 mg
1 mg
500 mg
500 mg
25 mg
500 mg
300 mg
1 mg
500 mg
A small number of patients who had
failed on combination chemotherapy have
been given intravenous bleomycin. The
initial results in this group have not been
encouraging but the numbers thus treated
are as yet too small to form any conclusions.
Advanced head and neck cancer almost
invariably has some visible or palpable
manifestations. The criteria of response to
treatment were therefore classified as: com-
plete regression-disappearance of visible or
palpable disease; partial regression-reduc-
tion in size of visible or palpable disease
by 50% or more; control-no obvious
progression of disease; nil-steady progres-
sion of disease.
RESULTS
The patients, their medical histories
and responses to treatment are sum-
marized in Table II-IV. The overall re-
sponse rates are summarized in Table V.
Those patients in whom the response
is given as " control " are thus classified
with considerable reservation. Squamous
cell carcinomata of the head and neck
are frequently slow growing lesions. In-
deed, at least 8 of the patients survived
for a minimum of 4 months from the
time all active treatment was stopped.
Small changes in size, especially if the
patient was seen by different observers,
would be difficult to confirm. For this
reason it is felt that " control ", or no
evidence ofdisease progression, for periods
of 3 months or less may mean no more
than that the disease was progressing
at a pace too slow to be observed clinic-
ally.
Patients treated with methotrexate as a
single agent
Of40 patients, only 3 showed objective
(partial) regression of disease. Seven
patients had their disease controlled by
therapy but of these only 2 were con-
trolled for longer than 3 months. Of
these 2, one had received radiotherapy
immediately before starting chemotherapy
and it is thus impossible to say which
treatment resulted in control of his
disease. Of the remaining patients, none
showed any subjective relief from dis-
tressing symptoms such as pain, dysphagia
and general malaise. Thus, 10 out of
40 patients (25-0%) showed some response
to treatment but probably only 4 of
these were significant and 3 patients
(7*5%) showed actual regression ofdisease.
Only 8 patients (20.0%) reached or
exceeded the 50 mg per week dose level.
The reasons for failure are summarized in
Table VI. Of the 8 patients achieving
maximum dosage, 2 showed some regres-
tion of disease and 2 were controlled for
periods of 3 and 4 months respectively.
Thus, 37-5% of the group achieving
maximum dosage showed some significant
response to treatment.
Patients treated with combination chemo-
therapy after methotrexate
Of 16 patients, one showed complete
regression of disease, 2 partial regression
and 2 control for 2 and 4 months respect-
ively. Thus, 4 patients (25-0%) showed
a significant response to treatment. Of
these 4 patients, 2 had had an initial
response to methotrexate (both controlled
for over 4 months) and the other 2 had
shown no response to methotrexate.
Toxicity was noted in 7 patients.
Leucopenia led to a reduction in dose, and
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TABLE III.-Patients Treated with Quadruple Chemotherapy after Failure of Intravenous
Methotrexate
Patient
W. W.
G. D.
P. W.
Age
71
60
69
Sex
M
F
M
Site of primary
lesion
Larynx
Larynx
Epiglottis
G. G. 58 M Nasopharynx
C. E. 25 F Tongue
Z. M. 73 M Tongue
J. R. 69 M Floor of mouth
V. A. 63 F Buccal mucosa
H. H. 65 F Floor of mouth
L. F. 72 M Alveolus
B. E. 51 M Alveolus
J. B. 61 M Alveolus
R. B. 71 M Maxillary
antrum
A. 0. 61 M Ethmoid sinus
V. M. 63 M External ear
E. E. 68 F Lower lip
Previous treatment
Radiotherapy,
laryngectomy
Radiotherapy,
laryngectomy
Radiotherapy
Radiotherapy
Radiotherapy, block
dissection
Radiotherapy
Radiotherapy
Radiotherapy
Radiotherapy
Major excision and
reconstruction
Radiotherapy
Radiotherapy, major
excision and
reconstruction
Radiotherapy,
fenestration
Radiotherapy
Radiotherapy,
excision
Radiotherapy, major
excision and
reconstruction
Response
Nil
Nil
Control
Partial
regression
Nil
Nil
Nil
Nil
Nil
Nil
Control
Complete
regression
Nil
Nil
Partial
regression
Nil
Duration Toxicity
Leucopenia
- Nausea
4 months Peripheral
neuropathy,
alopecia
2 months Leucopenia
Nausea
Leucopenia
2 months
30 months Peripheral
neuropathy,
alopecia
3 months
symptomb suggestive of peripheral neuro-
pathy led to vinblastine being substituted
for vincristine. Despite the use of a
scalp tourniquet, 2 patients developed
total alopecia. Nausea was controlled
with routine antiemetics. In no case did
toxicity necessitate the cessation of treat-
ment.
Patients treated with combination chemo-
therapy only
Of 10 patients, one showed control
of disease for a period of 14 months, the
remaindershowednoresponsetotreatment.
Toxicity was noted in 4 patients-2
developed leucopenia and 2 complained of
nausea.
TABLE IV.-Patients Treated with Quadruple Chemotherapy with no Previous Intravenous
Methotrexate
Site of primary
Patient Age Sex lesion Previous treatment
J. C. 64 M Larynx Radiotherapy, laryngectomy
E. W. 64 F Larynx Radiotherapy, laryngectomy
G. B. 39 M Larynx Radiotherapy, laryngectomy
A. M. 68 M Pharynx Radiotherapy
N. P. 60 M Nasopharynx Radiotherapy
F. R. 52 F Tongue Radiotherapy
P. M. 57 M Tongue Radiotherapy, major exci-
sion and reconstruction J. W. 51 M Buccal mucosa Radiotherapy, major exci-
sion and reconstruction
P. P. 61 M Hard palate Radiotherapy, fenestration,
block dissection W. E. 69 M Maxillary Radiotherapy, major exci-
antrum sion and reconstruction
Duration
14 months
Toxicity
Leucopenia
Nausea
Nausea
Leucopenia
Response
Nil
Nil
Nil
Control
Nil
Nil
Nil
Nil
Nil
Nil
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TABLE V.-Overall Response to
Chemotherapy
Patients treated with methotrexate
Complete regression
Partial regression
Control
No response
0
3
7
30
Patients treated with combination chemotherapy
after methotrexate
Complete regression I
Partial regression 2
Control 2
No response 12
Patients treated with combination
only
Complete regression
Partial regression
Control
No response
chemotherapy
0
0
1
9
TABLE VI. Toxic Effects of Methotrexate
Necessitating Reduction of Dose
Leucopenia 14 cases
Oral discomfort 13 cases
Haemorrhage 3 cases
Anaemia 1 case
Certain other facts emerging from the
results
Major surgery in addition to radio-
therapy does not appear to prejudice the
chances of success with chemotherapy.
All the patients showing actual regression
of disease had been subjected to some
form of surgery in addition to radio-
therapy.
No particular primary site appears
more, or less, sensitive than any other to
chemotherapy.
Of the 50 patients in this series,
6 (12-0%) had chest x-rays demonstrating
pulmonary metastases.
DISCUSSION
In the early 1960s the chemothera-
peutic treatment of choice for advanced
squamous cell carcinoma of the head
and neck at this hospital was intra-
arterial perfusion with methotrexate
(Westbury et al., 1962; Westbury, 1963).
The high incidence of complications with
this technique and its relatively low
success rate led to its abandonment in
favour of intravenous chemotherapy in
view of the promising reports from other
centres.
The figures in this series are, however,
disappointing. Of the patients treated
with methotrexate alone, only 3 (7.5%)
showed objective regression of disease
compared with 57.0%O in the series
reported by Leone et al. (1968) and
60.0% in a smaller series reported by
Papac, Lefkowitz and Bertino (1967).
The most obvious difference between
this series and the two American papers
is one of dose regimen. Leone et al.
(1968) gave 60f0 mg/m2 once a week and
Papac et al. (1967) 0f8 mg/kg body
weight every 4 days. Both these authors,
however,reported moderate toxicityneces-
sitating a reduction of dosage down to
25% of the original level and in some
cases cessation oftreatment. Thus, apart
from the initial one or two injections,
the difference in dose between this series
and that of the two earlier papers is
less than it might at first appear.
Does a higher dosage correlate with
clinical improvement? The answer is
probably yes. Of the 3 patients showing
objective regression 2 were on doses of
50 mg or more weekly; the third, however,
never exceeded a dose of 20 mg.
Toxicity was noted in 25 of the
patients (62.5%). Leucopenia and oral
ulceration were the two commonest side-
effects. Sensitivity to methotrexate
varies widely from individual to individual
and it is impossible to predict in advance
which patient will tolerate the drug
(Hansen et al., 1971). It could be asked
if using folinic acid in conjunction with
methotrexate might not allow higher
dosage with less toxicity. This was not
employed in the American series and when
used in this hospital with intra-arterial
methotrexate no improvement in overall
response rate was noted.
The duration of regression in the 3
patients in this series was 4, 4 and 13
months respectively. Papac et al. (1967)
noted only short remissions with a median
of 2 months' duration, whereas remissions
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obtained by Leone et al. (1968) in their
series were mainly of the order of 3 to 4
months. Thus, even in the most opti-
mistic series the duration of remission is
usually brief.
Harrison (1963) reported a series of
patients with squamous cell carcinoma
of the head and neck treated by intra-
venous cyclophosphamide with encourag-
ing results. It might therefore be ex-
pected that combination chemotherapy
with cyclophosphamide and methotrexate
included in theregimenwould be especially
valuable in head and neck cancer.
Here again, the results are largely
discouraging. Of the two groups treated
only 5 out of 26 patients (190%) showed a
response to treatment.
The question of optimum dosage can
again be raised but toxic effects were
noted in 11 patients and doubtless higher
doses would have increased both the
number and severity of such effects.
It can be argued that such symptoms
as oral ulceration, nausea, alopecia, neuro-
pathy and the risk of infection and
haemorrhage can all be justified to obtain
regression of otherwise incurable disease.
Even in the best series, however, such
regressions are usually brief and it is
considered of doubtful benefit to give
someone with incurable, often disfiguring,
disease a few more months of life merely
tosuffer the side-effects ofintensive chemo-
therapy.
I would like to thank Dr I. W. F.
Hanham and Dr K. A. Newton for
allowing me to quote their cases and
for their valuable advice and criticism in
the preparation of this paper.
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